NCT05226455 - Venetoclax in Patients With MDS or AML in Relapse After AHSCT | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 23, 2022

Primary Completion Date

September 1, 2026

Study Completion Date

December 1, 2027

Conditions

MDSAML

Interventions

DRUG

venetoclax + azacitidine +/- donor lymphocyte infusion

Venetoclax will be given once daily orally on days 1 to 14 for all cycles. Venetoclax + azacitidine +/- donor lymphocyte infusion (12 cycles maximum)

Trial Locations (13)

31059

RECRUITING

IUCT Oncopole, Toulouse

33604

RECRUITING

CHU de Haut-Lévèque, Pessac

34295

RECRUITING

Hôpital Saint-Eloi, Montpellier

38043

RECRUITING

CHU de Grenoble, Grenoble

42270

NOT_YET_RECRUITING

Institut de Cancérologie de la Loire Lucien Neuwirth, Saint-Priest-en-Jarez

44093

NOT_YET_RECRUITING

CHU Hôtel Dieu, Nantes

49933

RECRUITING

CHU d'Angers, Angers

69495

RECRUITING

Centre Hospitalier Lyon-Sud, Pierre-Bénite

75010

RECRUITING

Hôpital Saint louis, Paris

76038

RECRUITING

Centre Henri Becquerel, Rouen

80054

NOT_YET_RECRUITING

CHU d'Amiens Picardie - Site sud, Amiens

87042

RECRUITING

Hôpital Dupuytren, Limoges

06200

RECRUITING

Hôpital l'Archet I, Nice